The institute recommended that existing GLP-1 makers, and those with products in the pipeline, should consider steep discounts to prices in exchange for higher volume. What has to happen is we have to move from a low-volume, high-price business model, to a high-volume, low-price business model, Nunn said
In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA)
Our data show that GLP-1RA/tesaglitazar improves glucose control with superior efficacy to the GLP-1RA or tesaglitazar alone and suggest that this conjugate might hold therapeutic value to acutely treat hyperglycaemia and insulin resistance
It works by stimulating your body's natural growth hormone release through two complementary pathways, so you get the benefits without shutting down your own production
Its been three weeks and I have 0 side effects so far